Phase III GBM brain cancer trial gets recommendation to continue based on Data Safety Monitoring Board’s safety review


Northwest Biotherapeutics, a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, has announced, in response to shareholder inquiries, that the Data Safety Monitoring Board (DSMB) has made an unblinded review of the safety data for the company’s ongoing international phase III glioblastoma multiforme (GBM) trial, and has recommended that the trial continue as planned.

The DSMB’s review of the efficacy data is still pending.  

Marnix Bosch, chief technical officer of Northwest Biotherapeutics notes, “We are pleased with the recommendation of the DSMB to continue the trial as planned. This is an important step in the ongoing progress of our phase III trial.”